KCT0004670
Completed
未知
A Multicenter, Open-label, Phase I/II Clinical Trial of Intraperitoneal Paclitaxel and Oral S-1 and Intravenous Oxaliplatin Combination Therapy in Patients with Advanced or Recurrent Gastric Cancer with Peritoneal metastasis
Myungmoon Pharm0 sites53 target enrollmentTBD
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Myungmoon Pharm
- Enrollment
- 53
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Selection criteria
- •(1\) Patients aged 20 years and under 80 years old
- •(2\) Patients whose ECOG performance is equal to 0 or 1;
- •(3\) Patients with progressive or recurrent carcinoma of the boundary of stomach or stomach esophagus accompanied by histologically or imagingally identified peritoneal pancreas (including the positive of peritoneal cytogen);
- •(4\) Patients who have signed a written consent form approved by the Agency's Research Ethics Review Committee to take part in this study after receiving a full explanation of the purpose and content of the test prior to their participation in the test.
Exclusion Criteria
- •Exclusion criteria
- •\- Related to methodology
- •(1\) Patients who have undergone surgery or chemotherapy for other long\-term primary cancer within the last five years (excluding completely cured basal cell or squamous cell skin cancer and intraepithelial cancer of the cervix)
- •(2\) Metastatic gastric adenocarcinoma or gastroesophageal borderline adenocarcinoma with confirmed HER2 overexpression (IHC 3\+ or IHC 2\+ and ISH positive) in primary tumors or metastatic lesions
- •(3\) Persons who have participated in other clinical trials and administered other clinical trial medications within 30 days prior to registration of this trial;
- •(4\) Within the last 6 months, any of the following applies:
- •? myocardial infarction
- •? Severe/unstable angina
- •? Coronation/peripheral artery bypass
- •? NYHA class III or IV congestive heart failure
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Phase 1
An Open-label, Phase I/II Multicenter Clinical Trial of NECVAX-NEO1 in Addition to Anti-PD-1 or Anti-PD-L1 Monoclonal Antibody Therapy in Patients with Solid Tumors (NECVAX-NEO1-02-INT).Advanced solid tumorsMedDRA version: 21.1Level: LLTClassification code: 10065252Term: Solid tumor Class: 10029104Therapeutic area: Not possible to specifyCTIS2024-511212-24-00EC Bio Therapeutics GmbH40
Completed
Phase 2
An open-label, Phase I/II multicenter clinical trial of VXM01 in combination with avelumab in patients with progressive glioblastoma following standard treatment, with or without second surgery.NL-OMON48738VAXIMM GmbH9
Active, not recruiting
Phase 1
An early phase clinical study of VXM01 in combination with avelumab in patients with brain cancer following standard treatment.Progressive glioblastoma (WHO grade IV)MedDRA version: 20.0 Level: PT Classification code 10018336 Term: Glioblastoma System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2017-003076-31-NLVAXIMM GmbH30
Active, not recruiting
Phase 1
An early phase clinical study of VXM01 in combination with avelumab in patients with brain cancer following standard treatment.EUCTR2017-003076-31-DEVAXIMM GmbH30
Active, not recruiting
Phase 1
An open-label, phase I/II multicenter clinical trial of NECVAX-NEO1 as add-on to first-line neoadjuvant anti-PD-1 monoclonal antibody therapy in patients with triple-negative breast cancerCTIS2024-512520-11-00EC Bio Therapeutics GmbH8